Innoviva Specialty Therapeutics

What Innoviva Specialty Therapeutics does

Innoviva Specialty Therapeutics is a Waltham, Massachusetts-based specialty pharmaceutical subsidiary of Innoviva, Inc. (NASDAQ: INVA), launched in May 2023 through the integration of two acquired entities, Entasis Therapeutics Holdings Inc. and La Jolla Pharmaceutical Company. The company develops and commercializes therapies for critical care and infectious diseases, with a portfolio of five FDA-approved products targeting high-mortality and drug-resistant conditions: GIAPREZA (angiotensin II) for septic and distributive shock, NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea, XACDURO (sulbactam-durlobactam) for carbapenem-resistant Acinetobacter infections, XERAVA (eravacycline) for complicated intra-abdominal infections, and ZEVTERA (ceftobiprole) for Staphylococcus aureus bacteremia and other bacterial infections.

The product portfolio is built around proprietary small-molecule chemistries with novel mechanisms of action, including the first pathogen-targeted therapy for Acinetobacter, the first-in-class spiropyrimidinetrione antibiotic, and the only FDA-approved cephalosporin for MRSA bacteremia. Several assets carry QIDP designation, conferring priority review and extended exclusivity. The company commercializes through specialty pharmacies and hospital distribution channels in the U.S. and through regional partners (Dr. Reddy's, Zai Lab, Basilea, PAION, Everest Medicines) internationally, generating revenue from direct product sales plus licensing royalties and milestone payments.

The business model combines unit-based product sales at premium WAC pricing ($525-$2,350 per dose) with upfront payments, milestones, and tiered royalties from international licensees. The company reported 51-100 employees and parent-level Q3 2025 revenue of $107.8 million (20% year-over-year growth). Strategic focus areas include antimicrobial resistance, with two major U.S. product launches (ZEVTERA, NUZOLVENCE) completed in 2025 and geographic expansion through six distribution partnerships covering more than 80 countries.

Name

Innoviva Specialty Therapeutics

Legal name

Innoviva Specialty Therapeutics, Inc.

Website

https://innovivaspecialtytherapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

51–100 employees

Short description

Innoviva Specialty Therapeutics is a Waltham, Massachusetts-based pharmaceutical subsidiary of Innoviva, Inc. that develops and commercializes five FDA-approved therapies for critical care and infectious diseases, targeting drug-resistant infections and life-threatening conditions in hospital settings through specialty pharmacy and international distribution partners.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Anti-Infective and Critical Care Therapeutics)

NAICS

Offices of Physicians (62111), Offices of Physicians (6211)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Specialty pharmaceuticals
• Critical care therapeutics
• Anti-infective therapies
• Antimicrobial resistance drugs
• Hospital injectable antibiotics

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Product Sales: Direct sales of marketed pharmaceutical products including GIAPREZA, NUZOLVENCE, XERAVA, XACDURO, and ZEVTERA to healthcare providers and hospital systems in the U.S.
2. Royalties and Milestone Payments: Receives upfront payments, regulatory and commercial milestone payments, and tiered royalties on net sales from distribution and licensing partners such as Dr. Reddy's for international markets.
3. Royalty Rights: Projected royalty rights from two inhaled therapies for COPD and asthma generating over $1.2 billion by 2030 as stated by BTIG analyst coverage.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Innoviva Specialty Therapeutics develops and commercializes FDA-approved specialty pharmaceutical therapies for critical care and infectious disease conditions, with a portfolio of five marketed products: GIAPREZA (angiotensin II) for septic/distributive shock, XERAVA (eravacycline) for complicated intra-abdominal infections, XACDURO (sulbactam-durlobactam) for Acinetobacter infections, ZEVTERA (ceftobiprole) for MRSA bacteremia and pneumonia, and NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea. The company sells these injectable and oral therapies to hospitals, healthcare systems, and specialty pharmacies primarily in the United States, supplemented by international licensing partnerships.

Product overview

Innoviva Specialty Therapeutics is a biotechnology company focused on critical care and infectious disease therapeutics. The company markets five FDA-approved products: GIAPREZA (angiotensin II) for septic/distributive shock, NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea, XACDURO (sulbactam-durlobactam) for Acinetobacter infections, XERAVA (eravacycline) for complicated intra-abdominal infections, and ZEVTERA (ceftobiprole) for MRSA and other bacterial infections. The portfolio addresses unmet needs in hospital settings and antimicrobial resistance.

Differentiator

Problem solved

Functional benefit

Brands

• IST: Abbreviated corporate reference used in press releases and official communications

Products and services

• GIAPREZA (angiotensin II) A vasoconstrictor injection that mimics the body's endogenous angiotensin II peptide to increase blood pressure in adults with septic or other distributive shock. Indicated for the treatment of vasopressor-dependent hypotension in critical care hospital settings.
• XERAVA (eravacycline) A tetracycline-class (fluorocycline) antibacterial injection for treating complicated intra-abdominal infections (cIAI) in adults caused by multidrug-resistant bacteria. Used in hospital settings.
• XACDURO (sulbactam for injection; durlobactam for injection) An antibiotic co-packaged for intravenous use specifically developed to target Acinetobacter baumannii-calcoaceticus complex infections causing hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in adults. A β-lactam/β-lactamase inhibitor combination.
• ZEVTERA (ceftobiprole medocaril sodium for injection) An advanced-generation cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against Gram-positive bacteria (including MRSA) and Gram-negative bacteria. FDA-approved for three indications: Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). The only FDA-approved cephalosporin for MRSA bacteremia.
• NUZOLVENCE (zoliflodacin) A first-in-class, single-dose oral antibiotic (spiropyrimidinetrione class) for treating uncomplicated urogenital gonorrhea in adults and adolescents. Inhibits bacterial type II topoisomerase with no cross-resistance to existing antibiotics. Addresses rising antibiotic resistance in gonorrhea treatment.

Quantifiable outcome

• Zoliflodacin demonstrated non-inferiority to ceftriaxone plus azithromycin in Phase 3 trial for uncomplicated gonorrhea
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• Dr. Reddy's Laboratories Ltd.coreChannel Partner/ Reseller/ Distributor · 16 June 2026Exclusive distribution and licensing agreement for XACDURO covering South and Central America, Caribbean, Russia, and CIS countries. Dr. Reddy's handles development, regulatory, and commercialization activities while Innoviva receives upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales.
• Basilea Pharmaceutica Ltd.coreOEM/ Whitelabel/ Licensing Partner · 16 December 2024Exclusive distribution and license agreement for U.S. commercialization of ZEVTERA (ceftobiprole). Innoviva received exclusive marketing rights in the U.S., Basilea received $4 million upfront payment plus tiered royalties and milestones on net sales. ZEVTERA developed by Basilea with FDA approval for three indications.
• Zai LabmajorChannel Partner/ Reseller/ Distributor · 20 May 2024Zai Lab received NMPA approval for XACDURO (sulbactam-durlobactam) for hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China.
• Global Antibiotics Research & Development Partnership (GARDP)coreStrategic or Co-development PartnerPublic-private partnership for development of NUZOLVENCE (zoliflodacin) for treatment of uncomplicated gonorrhea. GARDP retains rights to register and commercialize in over three-quarters of the world's countries including low-income, most middle-income, and several high-income countries.
• PAION Deutschland GmbHminorChannel Partner/ Reseller/ DistributorPAION markets GIAPREZA in Europe on behalf of La Jolla Pharma, LLC, and XERAVA in Europe.
• Everest Medicines LimitedminorChannel Partner/ Reseller/ DistributorEverest markets XERAVA in mainland China, Hong Kong, and Singapore. XERAVA was approved by China NMPA in March 2023, Hong Kong in September 2022, and Singapore in April 2020.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Melinta Therapeutics: Specialty antibiotic company marketing therapies for serious bacterial infections including MRSA and multidrug-resistant pathogens. Directly comparable to IST's infectious disease portfolio targeting similar hospital-treated resistant infections.
• Basilea Pharmaceutica: Switzerland-based anti-infectives company commercializing ZEVTERA/Mabelio in Europe and other markets. Direct comparable in the anti-infective specialty pharma space and also an existing licensing partner for IST.
• Spero Therapeutics: Clinical-stage biopharmaceutical company developing antibiotics for multidrug-resistant bacterial infections. Directly comparable as a specialty antibiotic developer targeting resistant Gram-negative pathogens.
• Paratek Pharmaceuticals: Commercial-stage specialty pharmaceutical company marketing NUZYRA (omadacycline), a tetracycline-class antibiotic for community-acquired pneumonia and skin infections. Direct competitor in the tetracycline-class anti-infective space.

Emerging players

• Cidara Therapeutics: Biotechnology company developing anti-infectives including antifungal therapies and antiviral Fc conjugates. Comparable as a focused anti-infective developer with hospital-channel products addressing resistant infections.

Broad incumbents

• Shionogi: Japanese pharmaceutical company with a significant anti-infectives franchise including cefiderocol (Fetroja). Comparable as a larger incumbent competitor in the hospital antibiotic market with overlapping resistant pathogen focus.
• Merck & Co. Global pharmaceutical major with a meaningful anti-infectives portfolio including ZERBAXA (ceftolozane-tazobactam). Comparable as a broad incumbent operating in the same hospital infectious disease channel, though antibiotics are a smaller part of its overall portfolio.
• Pfizer: Global pharmaceutical major with a hospital antibiotics portfolio including ZAVICEFTA (ceftazidime-avibactam) and ERAXIS. Comparable as a broad incumbent in the hospital anti-infective and critical care channel with overlapping customer base.
• AbbVie: Global pharmaceutical company with hospital and infectious disease offerings (e.g., DALVANCE, TEFLARO). Comparable as a broad incumbent operating in the same hospital channel for serious bacterial infections, with broader portfolio diversification.

Others

• Tetraphase Biosciences: Developer of eravacycline (XERAVA), now part of La Jolla Pharmaceutical Company which was integrated into Innoviva Specialty Therapeutics. Included as a relevant adjacent reference point for IST's XERAVA product history.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/innoviva-specialty-therapeutics
• Xx.com/innovivastx

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innoviva Specialty Therapeutics